Drug approvals

FILE - In this March 26, 2019, file photo, a baggage handler waits for luggage to arrive to sort and deliver to passengers at Dulles International Airport in Dulles, Va. The Transportation Security Administration has changed its cannabis policy to allow passengers to travel with some forms of CBD oil and a drug derived from marijuana that has been approved by the Food and Drug Administration. (AP Photo/Cliff Owen, File)
May 28, 2019 - 7:59 pm
WASHINGTON (AP) — The Transportation Security Administration has changed its cannabis policy to allow passengers to travel with some forms of CBD oil and a drug derived from marijuana that has been approved by the Food and Drug Administration. All forms of marijuana were previously prohibited in...
Read More
This photo provided by Novartis shows Zolgensma. The one-time gene therapy developed by Novartis, Zolgensma, will cost $2.125 million. It treats a rare condition called spinal muscular atrophy, or SMA, which strikes about 400 babies born in the U.S. each year. The therapy, given in a one-hour infusion, was approved for children under age 2 and will be available within two weeks. (Novartis via AP)
May 24, 2019 - 5:51 pm
U.S. regulators have approved the most expensive medicine ever, for a rare disorder that destroys a baby's muscle control and kills nearly all of those with the most common type of the disease within a couple of years. The treatment is priced at $2.125 million. Out-of-pocket costs for patients will...
Read More
This photo provided by Novartis shows Zolgensma. The one-time gene therapy developed by Novartis, Zolgensma, will cost $2.125 million. It treats a rare condition called spinal muscular atrophy, or SMA, which strikes about 400 babies born in the U.S. each year. The therapy, given in a one-hour infusion, was approved for children under age 2 and will be available within two weeks. (Novartis via AP)
May 24, 2019 - 2:35 pm
U.S. regulators have approved the most expensive medicine ever, for a disorder that destroys a baby's muscle control and kills nearly all of those with the most common variant of the disease within a couple years. The treatment is priced at $2.125 million. Out-of-pocket costs for patients will vary...
Read More
May 24, 2019 - 1:41 pm
U.S. regulators have approved the most expensive medicine ever, a therapy meant to cure a disorder that rapidly destroys a baby's muscle control and kills most within a couple years. The one-time gene therapy developed by Novartis, Zolgensma (zohl-JEN-smah), will cost $2.125 million. It treats a...
Read More
FILE - In this April 16, 2019, file photo, a woman exhales a puff of vapor from a Juul pen in Vancouver, Wash. Under intense scrutiny amid a wave of underage vaping, Juul is pushing into television with a multimillion-dollar campaign rebranding itself as a stop-smoking aid for adults trying to kick cigarettes. (AP Photo/Craig Mitchelldyer, File)
May 09, 2019 - 4:24 pm
WASHINGTON (AP) — The young models and the candy-colored graphics that helped propel Juul to the top of the e-cigarette market are gone. In their place are people like Carolyn, a 54-year-old former smoker featured in new TV commercials touting Juul as an alternative for middle-age smokers. "I don't...
Read More
FILE - In this April 16, 2019, file photo, a woman exhales a puff of vapor from a Juul pen in Vancouver, Wash. Under intense scrutiny amid a wave of underage vaping, Juul is pushing into television with a multimillion-dollar campaign rebranding itself as a stop-smoking aid for adults trying to kick cigarettes. (AP Photo/Craig Mitchelldyer, File)
May 09, 2019 - 3:42 pm
WASHINGTON (AP) — The young models and the candy-colored graphics that helped propel Juul to the top of the e-cigarette market are gone. In their place are people like Carolyn, a 54-year-old former smoker featured in new TV commercials touting Juul as an alternative for middle-age smokers. "I don't...
Read More
FILE - In this Friday, Jan. 4, 2018 file photo, a worker adds CBD oil to a drink at a coffee shop in Fort Lauderdale, Fla. Cannabidiol is one of more than 100 compounds found in marijuana. (Jennifer Lett/South Florida Sun-Sentinel via AP)/South Florida Sun-Sentinel via AP)
April 02, 2019 - 11:42 am
NEW YORK (AP) — U.S. regulators are planning a public hearing to collect more information on CBD in cosmetics, foods and other products as the cannabis compound spreads in popularity. CBD comes from marijuana or hemp plants but does not cause a high. People have been drawn to the extract because of...
Read More
FILE - This Oct. 14, 2015 file photo shows the Food & Drug Administration campus in Silver Spring, Md. On Friday, March 8, 2019, the FDA approved Roche’s Tecentriq, the first cancer immunotherapy for treating an aggressive type of breast cancer. (AP Photo/Andrew Harnik, File)
March 08, 2019 - 6:26 pm
The U.S. Food and Drug Administration has approved the first immunotherapy drug for breast cancer. Swiss drugmaker Roche's Tecentriq was OK'd Friday for treating advanced triple-negative breast cancer, which accounts for about 15 percent of cases. It's to be given with chemotherapy, the standard...
Read More
This photo provided by Janssen Global Services shows Spravato nasal spray. Spravato, a mind-altering medication related to the club drug Special K, won U.S. approval Tuesday, March 5, 2019, for patients with hard-to-treat depression, the first in a series of long-overlooked substances being reconsidered for severe forms of mental illness. (Janssen Global Services via AP)
March 06, 2019 - 12:11 am
WASHINGTON (AP) — A mind-altering medication related to the club drug Special K won U.S. approval Tuesday for patients with hard-to-treat depression, the first in a series of long-overlooked substances being reconsidered for severe forms of mental illness. The nasal spray from Johnson & Johnson...
Read More
This photo provided by Janssen Global Services shows Spravato nasal spray. Spravato, a mind-altering medication related to the club drug Special K, won U.S. approval Tuesday, March 5, 2019, for patients with hard-to-treat depression, the first in a series of long-overlooked substances being reconsidered for severe forms of mental illness. (Janssen Global Services via AP)
March 05, 2019 - 8:28 pm
WASHINGTON (AP) — A mind-altering medication related to the club drug Special K won U.S. approval Tuesday for patients with hard-to-treat depression, the first in a series of long-overlooked substances being reconsidered for severe forms of mental illness. The nasal spray from Johnson & Johnson...
Read More

Pages